These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19264919)

  • 41. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
    Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
    Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.
    Brunstein CG; Weisdorf DJ; DeFor T; Barker JN; Tolar J; van Burik JA; Wagner JE
    Blood; 2006 Oct; 108(8):2874-80. PubMed ID: 16804113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival.
    Kumar P; Defor TE; Brunstein C; Barker JN; Wagner JE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1394-400. PubMed ID: 19041062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes.
    Ru Y; Zhang X; Song T; Ding Y; Zhu Z; Fan Y; Xu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu Z; Chen S; Ma X; Chen F; Chen J; Wu D
    Bone Marrow Transplant; 2020 Sep; 55(9):1754-1762. PubMed ID: 32066862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
    Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute.
    Hou HA; Yao M; Tang JL; Chen YK; Ko BS; Huang SY; Tien HF; Chang HH; Lu MY; Lin TT; Lin KH; Hsiao CH; Lin CW; Chen YC
    Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
    Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
    Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
    Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
    Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. No effect of HLA-C mismatch after allogeneic hematopoietic stem cell transplantation with unrelated donors and T-cell depletion in patients with hematological malignancies.
    Magalhaes I; Uhlin M; Schaffer M; Sundin M; Hauzenberger D; Remberger M; Mattsson J
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28510343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of HLA 1-3-locus mismatch and antithymocyte globulin administration in unrelated bone marrow transplantation.
    Kawamura K; Kanda J; Ohashi K; Fukuda T; Iwato K; Eto T; Fujiwara SI; Mori T; Fukushima K; Ozawa Y; Uchida N; Ashida T; Ichinohe T; Atsuta Y; Kanda Y
    Ann Hematol; 2020 May; 99(5):1099-1110. PubMed ID: 32206853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Li JP; Zhang T; Zhong J; Chen J
    Hematology; 2007 Apr; 12(2):117-21. PubMed ID: 17454192
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
    Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.
    Fujimoto A; Hiramoto N; Yamasaki S; Inamoto Y; Ogata M; Sugio Y; Fukuda T; Uchida N; Ikegame K; Matsuoka KI; Shiratori S; Kondo T; Miyamoto T; Eto T; Ichinohe T; Kanda Y; Atsuta Y; Suzuki R;
    Hematol Oncol; 2020 Apr; 38(2):146-152. PubMed ID: 31953867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation.
    Chiang KY; Hazlett LJ; Godder KT; Abhyankar SH; Christiansen NP; van Rhee F; Lee CG; Bridges K; Parrish RS; Henslee-Downey PJ
    Bone Marrow Transplant; 2001 Dec; 28(12):1117-23. PubMed ID: 11803352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
    Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
    Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.